March 23, 2021 Thank you for the opportunity to provide this written statement regarding strategies to improve the safety of dermal fillers and ensure that patients are making informed decisions. I am Dr. Diana Zuckerman, president of the National Center for Health Research, a nonprofit think tank that scrutinizes the safety and effectiveness of medical […]
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Comments on USPSTF’s Draft Recommendation on Gestational Diabetes Screening
March 15, 2021. We support the USPSTF’s update to the 2014 recommendations for GDM screening in asymptomatic pregnant persons.
Read More »Testimony of Dr. Diana Zuckerman at the FDA Advisory Committee on Johnson & Johnson COVID Vaccine
The Johnson & Johnson vaccine seems to be effective, but not proven to be more effective for moderate or severe COVID than the Pfizer or Moderna vaccines. We asked FDA to stop the hype and require studies to continue.
Read More »NCHR’s Statement on the Lutonix 014DCB Device
February 17, 2021. There is no reasonable assurance that the Lutonix 014DCB device is effective and therefore no reasonable assurance that the benefits outweigh the risks.
Read More »NCHR’s Comments on AHRQ’s Draft Report on Improving Patient Safety
Identifying and implementing strategies to improve patient safety and reducing medical errors is of utmost importance, and we strongly support this draft report. However, we have concerns over the limited scope of the report, and the title should be revised to better reflect that scope.
Read More »